Grifols's Fibrin Sealant Approved by FDA for Children; Shares Rise

MT Newswires Live10-29

Grifols (GRFS) said Tuesday that its plasma-protein-based fibrin sealant for controlling surgical bleeding has been approved for pediatric patients by the US Food and Drug Administration.

The product, marketed as Vistaseal in the US and Canada by Johnson & Johnson (JNJ) MedTech under a collaboration with Grifols, promotes hemostasis and tissue sealing during surgery, according to Grifols.

The Spanish biopharmaceutical company said the fibrin sealant was previously approved for adults and children in Europe.

Shares of Grifols were up more than 4% and Johnson & Johnson added 0.1% in early trading Tuesday.

Price: 8.68, Change: +0.34, Percent Change: +4.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment